Skip to main content
Erschienen in: Indian Journal of Pediatrics 5/2016

13.02.2016 | Review Article

Current Updates on Classification, Diagnosis and Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

verfasst von: Manisha Madkaikar, Snehal Shabrish, Mukesh Desai

Erschienen in: Indian Journal of Pediatrics | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a life threatening hyperinflammatory syndrome characterized by excessive activation of macrophages and T cells resulting from defective cytotoxicity. Severe hyperinflammation caused by uncontrolled proliferation of activated lymphocytes and histiocytes (macrophages) secreting high amounts of inflammatory cytokines threatens the life of the patient and may lead to death unless arrested by appropriate treatment. HLH can be caused either by certain underlying genetic diseases (familial HLH), or may also occur due to particular triggers in patients with no known inherited disorder (acquired HLH). Due to life threatening nature of the disease, early diagnosis and initiation of immunosuppressive therapy is extremely important. HLH diagnosis is based on constellation of clinical manifestations and laboratory parameters which often overlap with those of severe infection or sepsis. Identification of patients with familial HLH and their underlying genetic defects requires specialized laboratory tests and is important for predicting relapses and planning early therapeutic hematopoietic stem cell transplantation (HSCT). A high suspicion and thorough clinical, immunological and genetic work-up is required for diagnosis of HLH. Prompt initiation of adequate treatment is essential for the survival. Substantial progress has been made in exploring the complex cause and pathophysiology of HLH and also in management of HLH patients.
Literatur
1.
Zurück zum Zitat Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012;63:233–46.CrossRefPubMed Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012;63:233–46.CrossRefPubMed
2.
Zurück zum Zitat Henter JI, Elinder G, Soder O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand. 1991;80:428–35.CrossRefPubMed Henter JI, Elinder G, Soder O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand. 1991;80:428–35.CrossRefPubMed
3.
Zurück zum Zitat Osugi Y, Hara J, Tagawa S, et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood. 1997;89:4100–3.PubMed Osugi Y, Hara J, Tagawa S, et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood. 1997;89:4100–3.PubMed
4.
Zurück zum Zitat Scott RB, Robb-Smith AHT. Histiocytic medullary reticulosis. Lancet. 1939;234:194–8.CrossRef Scott RB, Robb-Smith AHT. Histiocytic medullary reticulosis. Lancet. 1939;234:194–8.CrossRef
6.
Zurück zum Zitat Gholam C, Grigoriadou S, Gilmour KC, Gaspar HB. Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management. Clin Exp Immunol. 2011;163:271–83.CrossRefPubMedPubMedCentral Gholam C, Grigoriadou S, Gilmour KC, Gaspar HB. Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management. Clin Exp Immunol. 2011;163:271–83.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematol Am Soc Hematol Educ Program. 2009;127-31. Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematol Am Soc Hematol Educ Program. 2009;127-31.
8.
Zurück zum Zitat Waleed A, Bousfiha A, Casanova JL, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2014;22:162. Waleed A, Bousfiha A, Casanova JL, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2014;22:162.
9.
Zurück zum Zitat Dufourcq-Lagelouse R, Jabado N, Le Deist F, et al. Linkage of familial hemophagocytic lymphohistiocytosis to 10q21–22 and evidence for heterogeneity. Am J Hum Genet. 1999;64:172–9.CrossRefPubMedPubMedCentral Dufourcq-Lagelouse R, Jabado N, Le Deist F, et al. Linkage of familial hemophagocytic lymphohistiocytosis to 10q21–22 and evidence for heterogeneity. Am J Hum Genet. 1999;64:172–9.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Ohadi M, Lalloz MR, Sham P, et al. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3–22 by homozygosity mapping. Am J Hum Genet. 1999;64:165–71.CrossRefPubMedPubMedCentral Ohadi M, Lalloz MR, Sham P, et al. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3–22 by homozygosity mapping. Am J Hum Genet. 1999;64:165–71.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Feldmann J, Callebaut I, Raposo G, et al. Munc13–4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003;115:461–73.CrossRefPubMed Feldmann J, Callebaut I, Raposo G, et al. Munc13–4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003;115:461–73.CrossRefPubMed
12.
Zurück zum Zitat Zur Stadt U, Schmidt S, Kasper B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet. 2005;14:827–34.CrossRefPubMed Zur Stadt U, Schmidt S, Kasper B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet. 2005;14:827–34.CrossRefPubMed
13.
Zurück zum Zitat Cote M, Menager MM, Burgess A, et al. Munc18–2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J Clin Invest. 2009;119:3765–73.CrossRefPubMedPubMedCentral Cote M, Menager MM, Burgess A, et al. Munc18–2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J Clin Invest. 2009;119:3765–73.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Zur Stadt U, Rohr J, Seifert W, et al. Hennies. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18–2 and impaired binding to syntaxin 11. Am J Hum Genet. 2009;85:482–92.CrossRefPubMedPubMedCentral Zur Stadt U, Rohr J, Seifert W, et al. Hennies. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18–2 and impaired binding to syntaxin 11. Am J Hum Genet. 2009;85:482–92.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Mhatre S, Madkaikar M, Desai M, Ghosh K. Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis (FHL) patients in India. Blood Cells Mol Dis. 2015;54:250–7.CrossRefPubMed Mhatre S, Madkaikar M, Desai M, Ghosh K. Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis (FHL) patients in India. Blood Cells Mol Dis. 2015;54:250–7.CrossRefPubMed
16.
Zurück zum Zitat Barbosa MD, Barrat FJ, Tchernev VT, et al. Identification of mutations in two major mRNA isoforms of the chediak-higashi syndrome gene in human and mouse. Hum Mol Genet. 1997;6:1091–8.CrossRefPubMedPubMedCentral Barbosa MD, Barrat FJ, Tchernev VT, et al. Identification of mutations in two major mRNA isoforms of the chediak-higashi syndrome gene in human and mouse. Hum Mol Genet. 1997;6:1091–8.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Menasche G, Feldmann J, Fischer A, de Saint Basile G. Primary hemophagocytic syndromes point to a direct link between lymphocyte cytotoxicity and homeostasis. Immunol Rev. 2005;203:165–79.CrossRefPubMed Menasche G, Feldmann J, Fischer A, de Saint Basile G. Primary hemophagocytic syndromes point to a direct link between lymphocyte cytotoxicity and homeostasis. Immunol Rev. 2005;203:165–79.CrossRefPubMed
18.
Zurück zum Zitat Griscelli C, Durandy A, Guy-Grand D, Daguillard F, Herzog C, Prunieras M. A syndrome associating partial albinism and immunodeficiency. Am J Med. 1978;65:691–702.CrossRefPubMed Griscelli C, Durandy A, Guy-Grand D, Daguillard F, Herzog C, Prunieras M. A syndrome associating partial albinism and immunodeficiency. Am J Med. 1978;65:691–702.CrossRefPubMed
19.
Zurück zum Zitat Nagle DL, Karim MA, Woolf EA, et al. Identification and mutation analysis of the complete gene for chediak-higashi syndrome. Nat Genet. 1996;14:307–11.CrossRefPubMed Nagle DL, Karim MA, Woolf EA, et al. Identification and mutation analysis of the complete gene for chediak-higashi syndrome. Nat Genet. 1996;14:307–11.CrossRefPubMed
20.
Zurück zum Zitat Enders A, Zieger B, Schwarz K, et al. Lethal hemophagocytic lymphohistiocytosis in hermansky-pudlak syndrome type II. Blood. 2006;108:81–7.CrossRefPubMed Enders A, Zieger B, Schwarz K, et al. Lethal hemophagocytic lymphohistiocytosis in hermansky-pudlak syndrome type II. Blood. 2006;108:81–7.CrossRefPubMed
21.
Zurück zum Zitat Dell'Angelica EC, Shotelersuk V, Aguilar RC, Gahl WA, Bonifacino JS. Altered trafficking of lysosomal proteins in hermansky-pudlak syndrome due to mutations in the beta 3 a subunit of the AP-3 adaptor. Mol Cell. 1999;3:11–21.CrossRefPubMed Dell'Angelica EC, Shotelersuk V, Aguilar RC, Gahl WA, Bonifacino JS. Altered trafficking of lysosomal proteins in hermansky-pudlak syndrome due to mutations in the beta 3 a subunit of the AP-3 adaptor. Mol Cell. 1999;3:11–21.CrossRefPubMed
22.
Zurück zum Zitat Shotelersuk V, Dell'Angelica EC, Hartnell L, Bonifacino JS, Gahl WA. A new variant of hermansky-pudlak syndrome due to mutations in a gene responsible for vesicle formation. Am J Med. 2000;108:423–7.CrossRefPubMed Shotelersuk V, Dell'Angelica EC, Hartnell L, Bonifacino JS, Gahl WA. A new variant of hermansky-pudlak syndrome due to mutations in a gene responsible for vesicle formation. Am J Med. 2000;108:423–7.CrossRefPubMed
23.
Zurück zum Zitat Huizing M, Scher CD, Strovel E, et al. Nonsense mutations in ADTB3A cause complete deficiency of the beta3A subunit of adaptor complex-3 and severe hermansky-pudlak syndrome type 2. Pediatr Res. 2002;51:150–8.CrossRefPubMed Huizing M, Scher CD, Strovel E, et al. Nonsense mutations in ADTB3A cause complete deficiency of the beta3A subunit of adaptor complex-3 and severe hermansky-pudlak syndrome type 2. Pediatr Res. 2002;51:150–8.CrossRefPubMed
24.
Zurück zum Zitat Purtilo DT, Cassel C, Yang JP. Letter: fatal infectious mononucleosis in familial lymphohistiocytosis. N Engl J Med. 1974;291:736.PubMed Purtilo DT, Cassel C, Yang JP. Letter: fatal infectious mononucleosis in familial lymphohistiocytosis. N Engl J Med. 1974;291:736.PubMed
25.
Zurück zum Zitat Rigaud S, Fondaneche MC, Lambert N, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature. 2006;444:110–4.CrossRefPubMed Rigaud S, Fondaneche MC, Lambert N, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature. 2006;444:110–4.CrossRefPubMed
26.
Zurück zum Zitat Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2- domain encoding gene. Nat Genet. 1998;20:129–35.CrossRefPubMed Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2- domain encoding gene. Nat Genet. 1998;20:129–35.CrossRefPubMed
27.
Zurück zum Zitat Schmid JP, Canioni D, Moshous D, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood. 2011;117:1522–9.CrossRef Schmid JP, Canioni D, Moshous D, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood. 2011;117:1522–9.CrossRef
28.
Zurück zum Zitat Marsh RA, Villanueva J, Kim MO, et al. Filipovich. Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. Clin Immunol. 2009;132:116–23.CrossRefPubMedPubMedCentral Marsh RA, Villanueva J, Kim MO, et al. Filipovich. Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. Clin Immunol. 2009;132:116–23.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Nichols KE, Ma CS, Cannons JL, Schwartzberg PL, Tangye SG. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol Rev. 2005;203:180–99.CrossRefPubMed Nichols KE, Ma CS, Cannons JL, Schwartzberg PL, Tangye SG. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol Rev. 2005;203:180–99.CrossRefPubMed
30.
Zurück zum Zitat Huck K, Feyen O, Niehues T, et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest. 2009;119:1350–8.CrossRefPubMedPubMedCentral Huck K, Feyen O, Niehues T, et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest. 2009;119:1350–8.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat van Montfrans JM, Hoepelman AI, Otto S, et al. CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. J Allergy Clin Immunol. 2012;129:787–93.CrossRefPubMedPubMedCentral van Montfrans JM, Hoepelman AI, Otto S, et al. CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. J Allergy Clin Immunol. 2012;129:787–93.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998;12:435–44.CrossRefPubMed Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998;12:435–44.CrossRefPubMed
33.
Zurück zum Zitat Tiab M, Mechinaud F, Harousseau J-L. Haemophagocytic syndrome associated with infections. Clin Haematol. 2000;13:163–78. Tiab M, Mechinaud F, Harousseau J-L. Haemophagocytic syndrome associated with infections. Clin Haematol. 2000;13:163–78.
34.
Zurück zum Zitat Rajagopala S, Dutta U, Chandra KS, Bhatia P, Varma N, Kochhar R. Visceral leishmaniasis associated hemophagocytic lymphohistiocytosis—case report and systematic review. J Infect. 2008;56:381–8.CrossRefPubMed Rajagopala S, Dutta U, Chandra KS, Bhatia P, Varma N, Kochhar R. Visceral leishmaniasis associated hemophagocytic lymphohistiocytosis—case report and systematic review. J Infect. 2008;56:381–8.CrossRefPubMed
35.
Zurück zum Zitat Henter JI, Ehrnst A, Andersson J, Elinder G. Familial hemophagocytic lymphohistiocytosis and viral infections. Acta Paediatr. 1993;82:369–72.CrossRefPubMed Henter JI, Ehrnst A, Andersson J, Elinder G. Familial hemophagocytic lymphohistiocytosis and viral infections. Acta Paediatr. 1993;82:369–72.CrossRefPubMed
36.
37.
Zurück zum Zitat Machaczka M, Vaktnas J, Klimkowska M, Hagglund H. Malignancy associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center. Leuk Lymphoma. 2011;52:613–9.CrossRefPubMed Machaczka M, Vaktnas J, Klimkowska M, Hagglund H. Malignancy associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center. Leuk Lymphoma. 2011;52:613–9.CrossRefPubMed
38.
Zurück zum Zitat Ramanan AV, Baildam EM. Macrophage activation syndrome is hemophagocytic lymphohistiocytosis–need for the right terminology. J Rheumatol. 2002;29:1105.PubMed Ramanan AV, Baildam EM. Macrophage activation syndrome is hemophagocytic lymphohistiocytosis–need for the right terminology. J Rheumatol. 2002;29:1105.PubMed
39.
Zurück zum Zitat Ishii E, Ohga S, Tanimura M, et al. Clinical and epidemiologic studies of familial hemophagocytic lymphohistiocytosis in Japan. Japan LCH study group. Med Pediatr Oncol. 1998;30:276–83.CrossRefPubMed Ishii E, Ohga S, Tanimura M, et al. Clinical and epidemiologic studies of familial hemophagocytic lymphohistiocytosis in Japan. Japan LCH study group. Med Pediatr Oncol. 1998;30:276–83.CrossRefPubMed
40.
Zurück zum Zitat Gurgey A, Gogus S, Ozyurek E, et al. Primary hemophagocytic lymphohistiocytosis in Turkish children. Pediatr Hematol Oncol. 2003;20:367–71.CrossRefPubMed Gurgey A, Gogus S, Ozyurek E, et al. Primary hemophagocytic lymphohistiocytosis in Turkish children. Pediatr Hematol Oncol. 2003;20:367–71.CrossRefPubMed
41.
Zurück zum Zitat Arico M, Janka G, Fischer A, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the international registry. FHL Leukemia. 1996;10:197–203.PubMed Arico M, Janka G, Fischer A, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the international registry. FHL Leukemia. 1996;10:197–203.PubMed
42.
Zurück zum Zitat Stinchcombe JC, Griffiths GM. Secretory mechanisms in cell-mediated cytotoxicity. Annu Rev Cell Dev Biol. 2007;23:495–517.CrossRefPubMed Stinchcombe JC, Griffiths GM. Secretory mechanisms in cell-mediated cytotoxicity. Annu Rev Cell Dev Biol. 2007;23:495–517.CrossRefPubMed
43.
Zurück zum Zitat Gupta S, Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy. Expert Rev Clin Immunol. 2010;6:137–54.CrossRefPubMed Gupta S, Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy. Expert Rev Clin Immunol. 2010;6:137–54.CrossRefPubMed
44.
Zurück zum Zitat Allen M, De Fusco C, Legrand F, et al. Familial hemophagocytic lymphohistiocytosis: how late can the onset be? Haematologica. 2001;86:499–503.PubMed Allen M, De Fusco C, Legrand F, et al. Familial hemophagocytic lymphohistiocytosis: how late can the onset be? Haematologica. 2001;86:499–503.PubMed
45.
Zurück zum Zitat Bhattacharyya M, Ghosh MK. Hemophagocytic lymphohistiocytosis-recent concept. J Assoc Physicians India. 2008;56:453–8.PubMed Bhattacharyya M, Ghosh MK. Hemophagocytic lymphohistiocytosis-recent concept. J Assoc Physicians India. 2008;56:453–8.PubMed
46.
47.
Zurück zum Zitat Chandrakasan S, Filipovich AH. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J Pediatr. 2013;163:1253–9.CrossRefPubMed Chandrakasan S, Filipovich AH. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J Pediatr. 2013;163:1253–9.CrossRefPubMed
48.
Zurück zum Zitat Lin T, Ferlic-Stark L, Allen C, Kozinetz C, McClain K. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer. 2011;56:154–5.CrossRefPubMedPubMedCentral Lin T, Ferlic-Stark L, Allen C, Kozinetz C, McClain K. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer. 2011;56:154–5.CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.CrossRefPubMed Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.CrossRefPubMed
50.
Zurück zum Zitat Schram AM, Campigotto F, Mullally A, et al. Marked hyperferritinemia does not predict for HLH in the adult population. Blood. 2015;125:1548–52.CrossRefPubMed Schram AM, Campigotto F, Mullally A, et al. Marked hyperferritinemia does not predict for HLH in the adult population. Blood. 2015;125:1548–52.CrossRefPubMed
51.
Zurück zum Zitat Shiota Y, Sato T, Ono T. Serum levels of soluble CD25 (soluble interleukin 2 receptor) in asthmatic patients. Arerugi. 1993;42:914–9.PubMed Shiota Y, Sato T, Ono T. Serum levels of soluble CD25 (soluble interleukin 2 receptor) in asthmatic patients. Arerugi. 1993;42:914–9.PubMed
52.
Zurück zum Zitat Tsuji T, Hirano T, Yamasaki H, Tsuji M, Tsuda H. A high sIL-2R/ferritin ratio is a useful marker for the diagnosis of lymphoma-associated hemophagocytic syndrome. Ann Hematol. 2014;93:821–6.CrossRefPubMedPubMedCentral Tsuji T, Hirano T, Yamasaki H, Tsuji M, Tsuda H. A high sIL-2R/ferritin ratio is a useful marker for the diagnosis of lymphoma-associated hemophagocytic syndrome. Ann Hematol. 2014;93:821–6.CrossRefPubMedPubMedCentral
53.
Zurück zum Zitat Chen WF, Xu J, Qiu HX, et al. Detection of serum neopterin in patients with hemophagocytic lymphohistiocytosis and its significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21:465–8.PubMed Chen WF, Xu J, Qiu HX, et al. Detection of serum neopterin in patients with hemophagocytic lymphohistiocytosis and its significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21:465–8.PubMed
54.
Zurück zum Zitat Xu XJ, Tang YM, Song H, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr. 2012;160:984–90.CrossRefPubMed Xu XJ, Tang YM, Song H, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr. 2012;160:984–90.CrossRefPubMed
55.
Zurück zum Zitat Molleran Lee S, Villanueva J, Sumegi J, et al. Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in north American families with haemophagocytic lymphohistiocytosis. J Med Genet. 2004;41:137–44.CrossRefPubMed Molleran Lee S, Villanueva J, Sumegi J, et al. Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in north American families with haemophagocytic lymphohistiocytosis. J Med Genet. 2004;41:137–44.CrossRefPubMed
56.
Zurück zum Zitat Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 2002;99:61–6.CrossRefPubMed Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 2002;99:61–6.CrossRefPubMed
57.
Zurück zum Zitat Bryceson YT, Pende D, Maul-Pavicic A, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood. 2012;119:2754–63.CrossRefPubMed Bryceson YT, Pende D, Maul-Pavicic A, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood. 2012;119:2754–63.CrossRefPubMed
58.
Zurück zum Zitat Madkaikar M, Mishra A, Desai M, Gupta M, Mhatre S, Ghosh K. Comprehensive report of primary immunodeficiency disorders from a tertiary care center in India. J Clin Immunol. 2013;33:507–12.CrossRefPubMed Madkaikar M, Mishra A, Desai M, Gupta M, Mhatre S, Ghosh K. Comprehensive report of primary immunodeficiency disorders from a tertiary care center in India. J Clin Immunol. 2013;33:507–12.CrossRefPubMed
59.
Zurück zum Zitat Trottestam H, Horne A, Aricò M. et al; Histiocyte Society. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118:4577–84.CrossRefPubMedPubMedCentral Trottestam H, Horne A, Aricò M. et al; Histiocyte Society. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118:4577–84.CrossRefPubMedPubMedCentral
60.
Zurück zum Zitat Mahlaoui N, Ouachée-Chardin M, de Saint BG, et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics. 2007;120:e622–8.CrossRefPubMed Mahlaoui N, Ouachée-Chardin M, de Saint BG, et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics. 2007;120:e622–8.CrossRefPubMed
61.
Zurück zum Zitat Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60:101–9.CrossRefPubMedPubMedCentral Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60:101–9.CrossRefPubMedPubMedCentral
62.
Zurück zum Zitat Milone MC, Tsai DE, Hodinka RL, et al. Nichols. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood. 2005;105:994–6.CrossRefPubMed Milone MC, Tsai DE, Hodinka RL, et al. Nichols. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood. 2005;105:994–6.CrossRefPubMed
63.
Zurück zum Zitat Sieni E, Cetica V, Piccin A, et al. Familial hemophagocytic lymphohistiocytosis may present during adulthood: clinical and genetic features of a small series. PLoS ONE. 2012;7:e44649.CrossRefPubMedPubMedCentral Sieni E, Cetica V, Piccin A, et al. Familial hemophagocytic lymphohistiocytosis may present during adulthood: clinical and genetic features of a small series. PLoS ONE. 2012;7:e44649.CrossRefPubMedPubMedCentral
Metadaten
Titel
Current Updates on Classification, Diagnosis and Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
verfasst von
Manisha Madkaikar
Snehal Shabrish
Mukesh Desai
Publikationsdatum
13.02.2016
Verlag
Springer India
Erschienen in
Indian Journal of Pediatrics / Ausgabe 5/2016
Print ISSN: 0019-5456
Elektronische ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-016-2037-y

Weitere Artikel der Ausgabe 5/2016

Indian Journal of Pediatrics 5/2016 Zur Ausgabe

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.